| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ... New England Journal of Medicine 351 (15), 1502-1512, 2004 | 7443 | 2004 |
| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5423 | 2012 |
| Pembrolizumab as second-line therapy for advanced urothelial carcinoma J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ... New England Journal of Medicine 376 (11), 1015-1026, 2017 | 3457 | 2017 |
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study DR Berthold, GR Pond, F Soban, R De Wit, M Eisenberger, IF Tannock Journal of Clinical Oncology 26 (2), 242-245, 2008 | 1499 | 2008 |
| First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase … AV Balar, D Castellano, PH O'Donnell, P Grivas, J Vuky, T Powles, ... The Lancet Oncology 18 (11), 1483-1492, 2017 | 1353 | 2017 |
| The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial … PJ Hesketh, SM Grunberg, RJ Gralla, DG Warr, F Roila, R De Wit, ... Journal of clinical oncology 21 (22), 4112-4119, 2003 | 971 | 2003 |
| Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin … M De Santis, J Bellmunt, G Mead, JM Kerst, M Leahy, P Maroto, T Gil, ... Journal of clinical oncology 30 (2), 191-199, 2012 | 804 | 2012 |
| European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I S Krege, J Beyer, R Souchon, P Albers, W Albrecht, F Algaba, M Bamberg, ... European urology 53 (3), 478-496, 2008 | 786 | 2008 |
| European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) HJ Schmoll, R Souchon, S Krege, P Albers, J Beyer, C Kollmannsberger, ... Annals of Oncology 15 (9), 1377-1399, 2004 | 665 | 2004 |
| Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer R de Wit, J de Bono, CN Sternberg, K Fizazi, B Tombal, C Wülfing, ... New England Journal of Medicine 381 (26), 2506-2518, 2019 | 660 | 2019 |
| Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study ES Antonarakis, JM Piulats, M Gross-Goupil, J Goh, K Ojamaa, ... Journal of Clinical Oncology 38 (5), 395-405, 2020 | 647 | 2020 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 544 | 2021 |
| Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial RTD Oliver, MD Mason, GM Mead, H von der Maase, GJS Rustin, JK Joffe, ... The Lancet 366 (9482), 293-300, 2005 | 534 | 2005 |
| Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior … J Bellmunt, H von der Maase, GM Mead, I Skoneczna, M De Santis, ... Journal of Clinical Oncology 30 (10), 1107-1113, 2012 | 531 | 2012 |
| Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer AW van den Belt-Dusebout, R de Wit, JA Gietema, S Horenblas, ... Journal of Clinical Oncology 25 (28), 4370-4378, 2007 | 512 | 2007 |
| Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists M de Boer-Dennert, R De Wit, PIM Schmitz, J Djontono, G Stoter, ... British journal of cancer 76 (8), 1055-1061, 1997 | 487 | 1997 |
| Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 years of follow-up Y Fradet, J Bellmunt, DJ Vaughn, JL Lee, L Fong, NJ Vogelzang, ... Annals of Oncology 30 (6), 970-976, 2019 | 458 | 2019 |
| A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis AJ Armstrong, ES Garrett-Mayer, YCO Yang, R De Wit, IF Tannock, ... Clinical Cancer Research 13 (21), 6396-6403, 2007 | 435 | 2007 |
| Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label … CN Sternberg, I Skoneczna, JM Kerst, P Albers, SD Fossa, M Agerbaek, ... The lancet oncology 16 (1), 76-86, 2015 | 429 | 2015 |
| Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study AV Balar, AM Kamat, GS Kulkarni, EM Uchio, JL Boormans, M Roumiguié, ... The Lancet Oncology 22 (7), 919-930, 2021 | 422 | 2021 |